Barrington Research Reiterates "Outperform" Rating for Paysign (NASDAQ:PAYS)

Paysign (NASDAQ:PAYS - Get Free Report)'s stock had its "outperform" rating restated by Barrington Research in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $7.00 target price on the stock. Barrington Research's price target indicates a potential upside of 228.64% from the stock's current price.

Separately, Lake Street Capital initiated coverage on Paysign in a research note on Friday, December 20th. They issued a "buy" rating and a $6.00 price target for the company.

Paysign Trading Down 0.9 %

Shares of PAYS traded down $0.02 during mid-day trading on Wednesday, reaching $2.13. 430,362 shares of the stock traded hands, compared to its average volume of 224,030. The company has a market cap of $114.48 million, a price-to-earnings ratio of 14.20 and a beta of 0.93. Paysign has a 1 year low of $2.10 and a 1 year high of $5.59. The firm has a fifty day moving average price of $2.62 and a 200 day moving average price of $3.21.

Paysign (NASDAQ:PAYS - Get Free Report) last announced its quarterly earnings data on Tuesday, March 25th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.02. The company had revenue of $15.61 million during the quarter, compared to analysts' expectations of $15.42 million. Paysign had a net margin of 14.28% and a return on equity of 30.64%. On average, sell-side analysts anticipate that Paysign will post 0.21 EPS for the current year.

Insiders Place Their Bets

In other news, major shareholder Topline Capital Partners, Lp sold 20,834 shares of Paysign stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $3.03, for a total value of $63,127.02. Following the transaction, the insider now directly owns 5,611,128 shares in the company, valued at approximately $17,001,717.84. This trade represents a 0.37 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Mark Newcomer sold 100,000 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $2.73, for a total value of $273,000.00. Following the sale, the chief executive officer now owns 8,936,886 shares of the company's stock, valued at approximately $24,397,698.78. This represents a 1.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 695,900 shares of company stock valued at $2,106,810 over the last three months. 23.40% of the stock is owned by company insiders.

Institutional Trading of Paysign

Several institutional investors have recently bought and sold shares of PAYS. PDT Partners LLC acquired a new stake in Paysign in the 4th quarter valued at about $39,000. Wells Fargo & Company MN boosted its stake in shares of Paysign by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 15,385 shares of the company's stock valued at $46,000 after purchasing an additional 5,243 shares during the period. SG Americas Securities LLC increased its position in shares of Paysign by 33.5% during the fourth quarter. SG Americas Securities LLC now owns 15,508 shares of the company's stock worth $47,000 after acquiring an additional 3,895 shares during the period. Virtu Financial LLC acquired a new position in shares of Paysign during the fourth quarter worth about $78,000. Finally, Occudo Quantitative Strategies LP increased its position in shares of Paysign by 56.5% in the 4th quarter. Occudo Quantitative Strategies LP now owns 28,429 shares of the company's stock valued at $86,000 after purchasing an additional 10,268 shares during the last quarter. 25.89% of the stock is owned by institutional investors and hedge funds.

About Paysign

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.